The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis

Journal of Neural Transmission

Volumn 117, Issue 11, 2010, Pages 1319-1325

  Rundfeldt, Chris ^a   Socała, Katarzyna ^b   Wlaź, Piotr ^b  

^a Drug ConsultNet   (Germany)

^b MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

Author keywords

Avolition; Mouse swim test; Neuroleptic; PDE 10A1; PDE 2A3; PDE 4A1; Phosphodiesterase; Psychosis

Indexed keywords

ANXIOLYTIC AGENT; DIZOCILPINE; ISOENZYME; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV A1; PHOSPHODIESTERASE XA1; TOFISOPAM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; IMMOBILIZATION; MALE; MOUSE; NEGATIVE SYNDROME; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; TRANQUILIZING ACTIVITY; VOMITING;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; DISEASE MODELS, ANIMAL; ISOENZYMES; MALE; MICE; PHOSPHORIC DIESTER HYDROLASES; PSYCHOTIC DISORDERS;

EID: 78651241027     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-010-0507-3     Document Type: Article

References (29)

1. SM Abdel-Naby Y Noda HM Mahmoud T Mamiya T Nagai H Furukawa T Nabeshima 2001 Enhancement of immobility induced by repeated phencyclidine injection: association with c-Fos protein in the mouse brain Behav Brain Res 124 71 76 10.1016/S0166-4328(01)00235-2 (Pubitemid 32567560)
2. F Andrási K Horváth E Sineger P Berzsenyi J Borsy A Kenessey M Tarr T Láng J Korösi T Hámori 1987 Neuropharmacology of a new psychotropic 2,3-benzodiazepine Arzneimittelforschung 37 1119 1124 2893623
3. J Arnt T Skarsfeldt 1998 Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence Neuropsychopharmacology 18 63 101 1:CAS:528:DyaK1cXht1GhsQ%3D%3D 10.1016/S0893-133X(97)00112-7 9430133 (Pubitemid 28026679)
4. P Bernard C Dufresne-Favetta P Favetta QT Do F Himbert S Zubrzycki T Scior C Lugnier 2008 Application of drug repositioning strategy to TOFISOPAM Curr Med Chem 15 3196 3203 1:CAS:528:DC%2BD1MXptV2ntg%3D%3D 10.2174/ 092986708786848488 19075663
5. TD Bethke GM Bohmer R Hermann B Hauns R Fux K Morike M David D Knoerzer W Wurst CH Gleiter 2007 Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor J Clin Pharmacol 47 26 36 1:CAS:528: DC%2BD2sXht1altbo%3D 10.1177/0091270006294529 17192499 (Pubitemid 44973995)
6. FG Boess M Hendrix FJ van der Staay C Erb R Schreiber W van Staveren J de Vente J Prickaerts A Blokland G Koenig 2004 Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance Neuropharmacology 47 1081 1092 1:CAS:528:DC%2BD2cXhtVSltLnO 10.1016/j. neuropharm.2004.07.040 15555642 (Pubitemid 39535847)
7. K Domek-Łopacińska JB Strosznajder 2008 The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging Brain Res 1216 68 77 10.1016/j.brainres.2008.02.108 18499090
8. SK Field 2008 Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma Expert Opin Investig Drugs 17 811 818 1:CAS:528:DC%2BD1cXlt1Shs7o%3D 10.1517/13543784.17.5.811 18447606 (Pubitemid 351843624)
9. M Goenen 1989 Historical perspectives and update of amrinone J Cardiothorac Anesth 3 15 23 1:STN:280:DyaK38zivF2itg%3D%3D 10.1016/0888-6296(89) 90055-0 2521046 (Pubitemid 20029372)
10. K Horváth F Andrási P Berzsenyi M Pátfalusi M Patthy G Szabó L Sebestyén E Bagdy J Korösi P Botka T Hámori T Láng 1989 A new psychoactive 5H-2,3-benzodiazepine with a unique spectrum of activity Arzneimittelforschung 39 894 899 2573361
11. EJ Horváth M Palkovits Z Lenkei KI Gyüre MI Fekete P Arányi 1994 Autoradiographic localization and quantitative determination of specific binding sites of anxiolytic homophthalazines (formerly called 2,3-benzodiazepines) in the striato-pallido-nigral system of rats Brain Res Mol Brain Res 22 211 218 10.1016/0169-328X(94)90049-3 8015381 (Pubitemid 24063642)
12. EJ Horváth K Horváth T Hámori MI Fekete S Sólyom M Palkovits 2000 Anxiolytic 2,3-benzodiazepines, their specific binding to the basal ganglia Prog Neurobiol 60 309 342 10.1016/S0301-0082(99) 00020-9 10670703
13. SJ Kanes J Tokarczyk SJ Siegel W Bilker T Abel MP Kelly 2007 Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity Neuroscience 144 239 246 1:CAS:528:DC%2BD28Xht12qsLvK 10.1016/j.neuroscience. 2006.09.026 17081698 (Pubitemid 44839057)
14. I Klebovich M Abermann 1993 Pharmacokinetics and metabolism of tofizopam (Grandaxin) Acta Pharm Hung 63 83 90 1:CAS:528:DyaK3sXkvVGisrc%3D 8100113
15. Láng T, Korösi J, Zólyomi G, Hámori T, Botka P (1985) Design and synthesis of 5H-2,3-benzodiazepines. In: Vizi ES, Furst S, Zsilla G (eds) Proc. 4th Cong. Hung. Pharmacol. Soc., Pergamon Press and Publishing House of the Hungarian Academy of Sciences, Oxford and Budapest, pp 91-97
16. S MacKenzie S Hastings C Wells 2010 Cyclic nucleotide phosphodiesterase assay technology Curr Protoc Pharmacol 49 3.12.1 3.12.26
17. A Masood Y Huang H Hajjhussein L Xiao H Li W Wang A Hamza CG Zhan JM O'Donnell 2009 Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling J Pharmacol Exp Ther 331 690 699 1:CAS:528:DC%2BD1MXhtlKnu7rP 10.1124/jpet.109.156729 19684253
18. Nielsen EB, Kehler J, Nielsen J, Brøsen P (2007) Patent: use of tofisopam as a PDE10A inhibitor. WO 2007/082546 A1
19. Y Noda K Yamada H Furukawa T Nabeshima 1995 Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia Br J Pharmacol 116 2531 2537 1:CAS:528: DyaK2MXptlertLY%3D 8581295
20. Y Noda H Kamei T Mamiya H Furukawa T Nabeshima 2000 Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions Neuropsychopharmacology 23 375 387 1:CAS:528:DC%2BD3cXmtlGls7c%3D 10.1016/S0893-133X(00)00138-X 10989264
21. L Petocz 1993 Pharmacologic effects of tofizopam (Grandaxin) Acta Pharm Hung 63 79 82 1:CAS:528:DyaK3sXktF2ktLc%3D 8100112
22. CJ Schmidt DS Chapin J Cianfrogna ML Corman M Hajos JF Harms WE Hoffman LA Lebel SA McCarthy FR Nelson C Proulx-LaFrance MJ Majchrzak AD Ramirez K Schmidt PA Seymour JA Siuciak FD Tingley III RD Williams PR Verhoest FS Menniti 2008 Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia J Pharmacol Exp Ther 325 681 690 1:CAS:528:DC%2BD1cXlsVOjtL8%3D 10.1124/jpet.107.132910 18287214 (Pubitemid 351574819)
23. TF Seeger B Bartlett TM Coskran JS Culp LC James DL Krull J Lanfear AM Ryan CJ Schmidt CA Strick AH Varghese RD Williams PG Wylie FS Menniti 2003 Immunohistochemical localization of PDE10A in the rat brain Brain Res 985 113 126 1:CAS:528:DC%2BD3sXntVymtLc%3D 10.1016/S0006-8993(03)02754-9 12967715 (Pubitemid 37088176)
24. JA Siuciak 2008 The role of phosphodiesterases in schizophrenia: therapeutic implications CNS Drugs 22 983 993 1:CAS:528:DC%2BD1MXmtlOnsw%3D%3D 10.2165/0023210-200822120-00002 18998737
25. JA Siuciak DS Chapin JF Harms LA Lebel SA McCarthy L Chambers A Shrikhande S Wong FS Menniti CJ Schmidt 2006 Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis Neuropharmacology 51 386 396 1:CAS:528:DC%2BD28XntFSnurY%3D 10.1016/j. neuropharm.2006.04.013 16780899 (Pubitemid 44061894)
26. J Szego M Somogyi E Papp 1993 Excerpts from the clinical-pharmacologic and clinical studies of Grandaxin Acta Pharm Hung 63 91 98 8100114
27. M Tóth A Bereczki S Drabant KB Nemes B Varga G Grézal J Tömlo G Lakner I Klebovich 2006 Gas chromatography nitrogen phosphorous detection (GC-NPD) assay of tofisopam in human plasma for pharmacokinetic evaluation J Pharm Biomed Anal 41 1354 1359 10.1016/j.jpba.2006.03.033 16682162 (Pubitemid 44218683)
28. PR Verhoest DS Chapin M Corman K Fonseca JF Harms X Hou ES Marr FS Menniti F Nelson R O'Connor J Pandit C Proulx-LaFrance AW Schmidt CJ Schmidt JA Suiciak S Liras 2009 Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4- yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia J Med Chem 52 5188 5196 1:CAS:528:DC%2BD1MXovFKmu7Y%3D 10.1021/jm900521k 19630403
29. A Vezzani R Serafini MA Stasi S Caccia I Conti RV Tridico R Samanin 1989 Kinetics of MK-801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats J Pharmacol Exp Ther 249 278 283 1:CAS:528: DyaL1MXit1Gnsro%3D 2540317